The phrase "a safety window" is correct and usable in written English.
It can be used in contexts related to safety measures, timeframes for actions, or physical barriers designed to protect individuals or property.
Example: "The construction site has a safety window to ensure that workers are protected from falling debris."
Alternatives: "a safety period" or "a protective barrier".
Therefore, a safety window of ( p_{wf} ) can be found.
Retrofitting existing windows with a safety window film, to improve impact resistance, has been increasing along with the awareness of potential attacks on strategic buildings.
In this paper, a versatile small-scale drop weight test set-up is conceived which is widely instrumented (accelerometer, force sensor, displacement sensor, high-speed visual observation) in order to gain more insight in the mechanical impact response of glass fitted with a safety window film.
A safety window of at least 10 s was observed in all cases.
Indeed, more recent data have suggested that tolcapone may have a wider safety window than previously believed.
To establish a temporal safety window for cryoablation at minimal temperatures and to assess the electrophysiological and histological changes as a function of the application duration.
Roflumilast is currently the only selective PDE4 inhibitor marketed for the treatment of chronic obstructive pulmonary disease, but has a narrow safety window [ 18].
This strategy may allow a larger safety window before toxic effects from non-autophagy-related effects of each drug are seen.
Therefore, the objectives of this study were to: (i) establish a temporal safety window during AV nodal cryoablation at minimal temperatures (−80°C); (ii) evaluate the residual electrophysiological AV nodal impairment after reversible lesions at −80°C; and (iii) assess the histological changes related to the occurrence of AVB as a function of the duration of the cryoablation application.
Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.
Although this may be surprising, we believe that this could be an indicator of the broad safety window of rivaroxaban in patients with complex co-morbidities, which would be in contrast to VKA therapy, which has a narrow therapeutic window.
